Leader Capital Markets Maintains Buy Rating on Teva with ILA9,300 Price Target

Teva (TEVA) has received a Buy rating from Leader Capital Markets with a price target of ILA9,300.00. Analyst Sabina Levi maintains a Buy rating, with a success rate of 25.00%. The company has a one-year high of ILA8,431.00 and a one-year low of ILA4,865.00, with an average volume of 2.11M.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has received a consensus rating of "Buy" from nine brokerages covering the company, as reported by Marketbeat Ratings. Seven analysts have recommended a buy, while two have assigned a strong buy rating. The average 1-year price target among these analysts is $24.13 [1].

Notable analysts include Truist Financial, which initiated coverage with a buy rating and a $25.00 target price, and Goldman Sachs Group, which also gave a buy rating with a $24.00 target price. JPMorgan Chase & Co. upgraded the stock from neutral to overweight with a target price increase from $21.00 to $23.00. Bank of America raised its price objective to $22.00, while UBS Group lowered its target to $23.00 [1].

In related news, insiders have been active in their trades. EVP Matthew Shields sold 6,206 shares at an average price of $17.02, reducing his ownership by 38.32% [1]. Institutional investors have also shown interest in the stock. Jones Financial Companies LLC increased its holdings by 145.4%, while Charles Schwab Investment Management Inc. boosted its position by 14.4% during the fourth quarter [1].

Teva Pharmaceutical Industries' stock traded down $0.17 during midday trading on July 2, 2025, hitting $16.84. The company's 52-week high is $22.80, and the 52-week low is $12.47. The stock has a market capitalization of $19.31 billion and a PE ratio of -14.64 [1].

Teva Pharmaceutical Industries reported $0.52 earnings per share (EPS) for the quarter, surpassing the consensus estimate of $0.47. The company's revenue was $3.89 billion, up 1.9% from the same quarter last year. Analysts anticipate 2.5 EPS for the current fiscal year [1].

Teva Pharmaceutical Industries develops, manufactures, and distributes generic medicines, specialty medicines, and biopharmaceutical products globally. The company offers a wide range of products, including generic medicines in various dosage forms and sterile products [1].

References:
[1] https://www.marketbeat.com/instant-alerts/teva-pharmaceutical-industries-ltd-nyseteva-receives-average-rating-of-buy-from-analysts-2025-07-07/